JEOL (6951) Q2 2026 earnings summary

Executive summary

• Q2 FY2025 net sales were ¥82.1B, down 5.9% year-over-year, and operating profit was ¥11.9B, down 24.6%.

• Profit attributable to owners of parent was ¥9.85B, down 9.8% year-over-year.

• Comprehensive income increased 7.2% year-over-year to ¥10.2B.

• Full-year FY2025 forecast: net sales ¥181B (down 8.0%), operating profit ¥24B (down 32.4–34.2%), profit attributable to owners of parent ¥18B (down 3.7%).

• Results exceeded internal 1H plan but reflect continued segment variations and external headwinds.

Financial highlights

• Q2 FY2025: net sales ¥82.1B, operating profit ¥11.9B, ordinary profit ¥12.9B, net profit ¥9.9B.

• Gross profit for the period was ¥39.3B, down from ¥43.1B year-over-year.

• Basic earnings per share was ¥192.55, compared to ¥213.60 in the previous year.

• Operating profit margin fell to 14.5% from 18.1% year-over-year.

• Cash and cash equivalents at period end were ¥34.3B, down from ¥37.7B at the previous period end.

Outlook and guidance

• Full-year forecast: net sales ¥181B, operating profit ¥24B, ordinary profit ¥24.5B, net profit ¥18B.

• Annual dividend forecast remains unchanged at ¥106 per share.

• Scientific/Metrology Instruments face uncertainty from US research funding cuts, US-China trade friction, and geopolitical risks.

• Industrial Equipment: single-beam and spot-beam mask writers performing well; multi-beam market delayed.

• Medical Equipment: steady demand in Japan, increased inquiries in China via WEGO; business transfer to Sysmex scheduled for April 2026.